SCHEMBL7562739

SCHEMBL7562739

NC(=O)c1ccc(C(=O)N2CCOCC2)nc1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.81
ALDH1A1 P00352 2/20 0.56
GRM5 P41594 2/20 0.50
HPGD P15428 5/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
POLB P06746 2/20 0.49
KDM4E B2RXH2 2/20 0.49
L3MBTL3 Q96JM7 1/20 0.49
ALOX15 P16050 1/20 0.49
HSD17B10 Q99714 1/20 0.49
PHGDH O43175 1/20 0.49
PRKAA2 P54646 2/20 0.47
PRKAB2 O43741 1/20 0.47
PRKAG1 P54619 1/20 0.47
PRKAA1 Q13131 1/20 0.47
PRKAG3 Q9UGI9 1/20 0.47
PRKAG2 Q9UGJ0 1/20 0.47
PRKAB1 Q9Y478 1/20 0.47
TSHR P16473 1/20 0.46
ESR2 Q92731 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13210615 0.89 SMN1; SMN2 (1.00) SMN1; SMN2ALDH1A1GRM5HPGDL3MBTL1
SCHEMBL1018513 0.87 SMN1; SMN2 (0.83) SMN1; SMN2ALDH1A1GRM5HPGDL3MBTL1
SCHEMBL3227298 0.82 SMN1; SMN2 (0.70) SMN1; SMN2ALDH1A1GRM5HPGDPHGDH
SCHEMBL1017672 0.82 SMN1; SMN2 (0.74) SMN1; SMN2ALDH1A1GRM5HPGDL3MBTL1
SCHEMBL6742231 0.81 SMN1; SMN2 (0.83) SMN1; SMN2ALDH1A1GRM5HPGDL3MBTL1
SCHEMBL30445048 0.80 SMN1; SMN2 (0.55) SMN1; SMN2ALDH1A1GRM5HPGDL3MBTL1
SCHEMBL17559403 0.79 SMN1; SMN2 (0.81) SMN1; SMN2ALDH1A1GRM5HPGDL3MBTL1
SCHEMBL2999369 0.79 PHGDH (0.69) SMN1; SMN2ALDH1A1HPGDL3MBTL1POLB
SCHEMBL28872982 0.79 SMN1; SMN2 (0.62) SMN1; SMN2ALDH1A1GRM5HPGDPOLB
SCHEMBL15008288 0.79 SMN1; SMN2 (0.70) SMN1; SMN2ALDH1A1GRM5HPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020068746-A1 Pyrrolo[2,3-d]pyrimidine compounds PFIZER INC. 2002-06-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020068746-A1 Pyrrolo[2,3-d]pyrimidine compounds JAK1, CDK2, JAK3 SMN1; SMN2 4219/4885ALDH1A1 1719/4885GRM5 3467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.